Evidence map›Paper›PMID 34522589›Full record

ReviewActa pharmaceutica Sinica. B2021

Evolution of blood-brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies.

Liang Han, Chen Jiang

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 178 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
178citing papers in PubMed, 2 pooled it
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

178 citing papers in PubMed, 2 syntheses or guidelines pooled it, 324 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Ceftazidime-avibactam versus polymyxin B for carbapenem-resistant gram-negative bacteria-associated post-neurosurgical meningitis: a retrospective comparative study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

118 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Liang HanJiangsu Key Laboratory of Neuropsychiatric Diseases Research, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
Chen JiangKey Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology, Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 200032, China.
Soochow University · CNState Key Laboratory of Medical Neurobiology

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blood-brain barrier (BBB) strictly controls matter exchange between blood and brain, and severely limits brain penetration of systemically administered drugs, resulting in ineffective drug therapy of brain diseases. However, during the onset and progression of brain diseases, BBB alterations evolve inevitably. In this review, we focus on nanoscale brain-targeting drug delivery strategies designed based on BBB evolutions and related applications in various brain diseases including Alzheimer's disease, Parkinson's disease, epilepsy, stroke, traumatic brain injury and brain tumor. The advances on optimization of small molecules for BBB crossing and non-systemic administration routes (

Indexed as

AD, Alzheimer's diseaseAMT, alpha-methyl-l-tryptophanAβ, amyloid betaBACE1, β-secretase 1BBB, blood–brain barrierBDNF, brain derived neurotrophic factorBlood–brain barrierBrain diseasesBrain-targetingBTB, blood–brain tumor barrierCMT, carrier-mediated transportationDrug delivery systemsDTPA-Gd, Gd-diethyltriaminepentaacetic acidEPR, enhanced permeability and retentionGd, gadoliniumGLUT1, glucose transporter-1ICAM-1, intercellular adhesion molecule-1KATP, ATP-sensitive potassium channelsKCa, calcium-dependent potassium channelsLAT1, L-type amino acid transporter 1LDL, low density lipoproteinLDLR, LDL receptorLFA-1, lymphocyte function associated antigen-1LRP1, LDLR-related protein 1MFSD2A, major facilitator superfamily domain-containing protein 2aMMP9, metalloproteinase-9MRI, magnetic resonance imagingNanoparticlesNPs, nanoparticlesPD, Parkinson's diseasePEG-PLGA, polyethyleneglycol-poly(lactic-co-glycolic acid)PEG, polyethyleneglycolP-gp, P-glycoproteinPLGA, poly(lactic-co-glycolic acid)PSMA, prostate-specific membrane antigenRAGE, receptor for advanced glycosylation end productsRBC, red blood cellRMT, receptor-mediated transcytosisROS, reactive oxygen speciessiRNA, short interfering RNATBI, traumatic brain injuryTfR, transferrin receptorTJ, tight junctiontPA, tissue plasminogen activatorVEGF, vascular endothelial growth factorZO1, zona occludens 1

Identifiers

PMID34522589
PMCPMC8424230
OpenAlexW3114264144

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.